Zacks: Brokerages Anticipate Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
Equities research analysts expect that Bio-Path Holdings Inc (NASDAQ:BPTH) will post earnings of ($0.02) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Bio-Path Holdings’ earnings. Bio-Path Holdings also posted earnings of ($0.02) per share during the same quarter last year. The firm is scheduled to report its next earnings results on Tuesday, August 8th.
On average, analysts expect that Bio-Path Holdings will report full-year earnings of ($0.09) per share for the current fiscal year. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Bio-Path Holdings.
Bio-Path Holdings (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, May 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01.
Several research firms recently commented on BPTH. HC Wainwright set a $5.00 price target on shares of Bio-Path Holdings and gave the company a “buy” rating in a report on Thursday, April 6th. Maxim Group set a $2.00 price target on shares of Bio-Path Holdings and gave the company a “buy” rating in a report on Wednesday, April 5th. Finally, Zacks Investment Research upgraded shares of Bio-Path Holdings from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Monday, March 20th.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/12/zacks-brokerages-anticipate-bio-path-holdings-inc-bpth-will-announce-earnings-of-0-02-per-share.html.
Bio-Path Holdings (NASDAQ:BPTH) traded down 0.0926% during midday trading on Friday, hitting $0.5395. 324,685 shares of the stock were exchanged. The stock’s market cap is $51.60 million. The firm has a 50 day moving average of $0.70 and a 200-day moving average of $0.97. Bio-Path Holdings has a 12-month low of $0.54 and a 12-month high of $2.83.
Several hedge funds have recently bought and sold shares of BPTH. HighTower Advisors LLC raised its stake in Bio-Path Holdings by 1.0% in the third quarter. HighTower Advisors LLC now owns 1,155,070 shares of the company’s stock worth $1,617,000 after buying an additional 12,000 shares in the last quarter. Geode Capital Management LLC raised its stake in Bio-Path Holdings by 0.8% in the first quarter. Geode Capital Management LLC now owns 688,183 shares of the company’s stock worth $569,000 after buying an additional 5,706 shares in the last quarter. Vanguard Group Inc. raised its stake in Bio-Path Holdings by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,912,516 shares of the company’s stock worth $2,409,000 after buying an additional 15,808 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares in the last quarter. Finally, State Street Corp raised its stake in Bio-Path Holdings by 4.3% in the fourth quarter. State Street Corp now owns 1,084,674 shares of the company’s stock worth $1,463,000 after buying an additional 44,747 shares in the last quarter. Institutional investors own 21.00% of the company’s stock.
About Bio-Path Holdings
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.